Prostate Cancer Training (PCaT): 3. Discussing with patients
Learning Objective: At the end of this module, you will learn how to assess the risk of prostate cancer in different patients and discuss screening for prostate cancer with patients using the shared decision making approach.
Prostate Cancer Training (PCaT): 3. Discussing with patients
"PSA results should be interpreted based on the risk of the patient."
This infographic shows the flow of management depending on the risk of the patient and the level of PSA results.
First, the assessment starts with family history to categorise patients' risk group.
Then, the PSA value should be interpreted differently based on the risk group.
The management plans for patients follow different PSA values for average risk vs moderate/high risk.
Click or zoom in to magnify the image.
References:
Prostate Cancer Foundation of Australia and Cancer Council Australia PSA Testing Guidelines Expert Advisory Panel. PSA testing and early management of test-detected prostate cancer. Prostate Cancer Foundation of Australia and Cancer Council Australia, Sydney (2016). Prostate Cancer Foundation of Australia and Cancer Council Australia.
Babjuk M, Burger M, Comperat E, Gontero P, Mostafid AH, Palou J. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office, Arnhem, The Netherlands. 2020.
Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860-864.
